Search

Displaying results 2541 - 2550 of 9670 in total
  1. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm. … [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

  2. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

  3. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections.

  4. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.

  5. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  6. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … side effects as that of the placebo.

  7. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  8. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    As an investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the … As an experimental drug, agmatine is being studied for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma

  9. Drug

    Vasopressin

    go.drugbank.com/drugs/DB00067
    ApprovedInvestigational

    [A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413] … It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock.

  10. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    It is marketed under the brand name Alvesco.